<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608322</url>
  </required_header>
  <id_info>
    <org_study_id>K23GM083211</org_study_id>
    <secondary_id>1K23GM083211-01</secondary_id>
    <nct_id>NCT00608322</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis</brief_title>
  <official_title>Randomized Double-blind Placebo-controlled Trial of Inhaled Nitric Oxide for the Treatment of Microcirculatory Dysfunction and Organ Failure in Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of General Medical Sciences (NIGMS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether inhaled nitric oxide is an effective
      treatment for microcirculatory dysfunction and acute organ system failure in the early stage
      of sepsis therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is a common and devastating disease that is responsible for 215,000 deaths annually in
      the United States and is the leading cause of death in critically ill patients. Sepsis is now
      recognized as a time-sensitive emergency, as patients stand the best chance for survival when
      effective therapeutic interventions are delivered as early as possible. Early goal-directed
      therapy (EGDT), a protocol-directed resuscitation strategy targeting early optimization of
      global hemodynamic parameters, can save lives. Use of an EGDT protocol has been associated
      with the largest mortality benefit demonstrated in sepsis randomized controlled trials to
      date; however, sepsis still carries an extremely high mortality rate (~30%), even with
      effective EGDT. As tissue perfusion in sepsis can remain markedly impaired despite
      normalization of global hemodynamics, targeting macrocirculatory goals of resuscitation (e.g.
      blood pressure, cardiac output) alone may not be sufficient.

      Microcirculatory dysfunction is a pivotal element in the pathogenesis of sepsis.
      Microcirculatory dysfunction causes impairment of tissue perfusion independent of global
      hemodynamics, and is hypothesized to be a critical factor in the development of
      sepsis-induced organ dysfunction, especially in the earliest phase of sepsis therapy.
      Orthogonal polarization spectral (OPS) videomicroscopy is a technique that permits
      non-invasive assessment of the microcirculation in human subjects. Using the OPS technique,
      increasing severity of early microcirculatory derangements in sepsis patients have been
      associated with acute multi-organ failure and mortality. We recently demonstrated that early
      derangements of microcirculatory flow in sepsis patients were more severe in non-survivors
      compared to survivors, even with the application of EGDT. Early recognition of
      microcirculatory dysfunction and its reversal may lead to improved outcome. Currently,
      however, there are no therapies to specifically target the microcirculation in sepsis. Novel
      strategies that go beyond optimization of global hemodynamics and aim to improve
      microcirculatory blood flow could be a new frontier for sepsis resuscitation. Since the early
      resuscitation phase of therapy represents the greatest opportunity for impact on clinical
      outcome in sepsis, it also appears to be the most promising window of opportunity to
      demonstrate a benefit when investigating novel therapies.

      Nitric oxide (NO) is an endogenous molecule that is essential for maintaining
      microcirculatory homeostasis. Nitric oxide becomes especially critical for protecting
      microcirculatory patency, integrity, and function when the microcirculation sustains a severe
      insult (e.g. sepsis). Although NO production is globally upregulated in sepsis, the
      production of NO is heterogeneous between and within organ systems at the microcirculatory
      level. We believe that exogenous NO administration may preserve microcirculatory flow in
      sepsis, and we hypothesize that this will be an effective therapy to augment tissue
      perfusion. Inhaled nitric oxide (iNO) can deliver NO effectively to the distal
      microcirculation and &quot;open&quot; low-flow microcirculatory units via modulation of microvascular
      tone as well as anti-adhesive effects on the microvascular endothelium. Because iNO would not
      be expected to induce or exacerbate arterial hypotension in sepsis patients, iNO
      administration is an ideal method to test hypotheses about the effects of exogenous NO on the
      microcirculation in sepsis.

      We hypothesize that iNO will augment microcirculatory perfusion in sepsis resuscitation, and
      this increase in microcirculatory flow will be associated with improved lactate clearance (an
      important marker of resuscitation effectiveness) and decreased organ failure (a critical
      patient-oriented outcome measure). To test our hypothesis, we generated two inter-related
      specific aims:

      Specific Aim 1: To determine whether iNO can augment tissue perfusion in sepsis
      resuscitation. In a randomized double-blind placebo-controlled trial, we will evaluate the
      effect of iNO compared to placebo on microcirculatory perfusion indices in sepsis patients
      who exhibit persistent microcirculatory flow impairment after achievement of global
      hemodynamic endpoints of resuscitation during EGDT.

      Specific Aim 2: To determine whether iNO-mediated improvement in microcirculatory perfusion
      in sepsis leads to more effective resuscitation and a reduction in organ failure. In a
      randomized double-blind placebo-controlled trial, we will evaluate the effect of iNO on
      clinical outcomes of sepsis patients: [(a) increase in lactate clearance from 0-2 hours, and
      (b) decrease in the Sequential Organ Failure Assessment (SOFA) score from 0 to 24 hours].
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>0-24 hours from protocol initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Sublingual Microcirculatory Flow Index (MFI)</measure>
    <time_frame>0-2 hours of study drug administration</time_frame>
    <description>The MFI is a continuous scale from 0-3, with 3.0 being better outcome and 0.0 being worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactate Clearance (Blood)</measure>
    <time_frame>0-2 hours of study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive inhaled nitric oxide (40 parts per million) for six hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects receive sham inhaled nitric oxide for six hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled nitric oxide</intervention_name>
    <description>Inhaled nitric oxide, 40 parts per million, for six hours.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>INOmax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham inhaled nitric oxide</intervention_name>
    <description>Sham inhaled nitric oxide administration, 0 parts per million, for six hours.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed or suspected infection (acute)

             PLUS:

          2. One or both of the following criteria for potential tissue hypoperfusion:

        (2a) systolic blood pressure &lt;90 mmHg despite 30cc/kg intravenous crystalloid challenge, OR
        (2b) serum lactate &gt;4 mmol/L.

        Exclusion Criteria:

          1. age &lt; 14 years

          2. pregnancy

          3. &quot;Do Not Resuscitate&quot; status (prior to enrollment)

          4. active clinically significant bleeding of any etiology

          5. status-post cardiac arrest

          6. need for immediate surgery

          7. inability to place a sublingual videomicroscopy probe under the tongue (e.g. inability
             to open the mouth or patient requirement of a high-flow face mask for supplemental
             oxygen [although videomicroscopy can be performed in patients with an endotracheal
             tube or nasal cannula])

          8. &gt;24 hours elapsed since first documented evidence of meeting criteria for potential
             tissue hypoperfusion (2a or 2b above).

          9. inability to obtain written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Trzeciak, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMDNJ-Robert Wood Johnson Medical School at Camden, Cooper University Hospital, Camden, New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Trzeciak S, Dellinger RP, Parrillo JE, Guglielmi M, Bajaj J, Abate NL, Arnold RC, Colilla S, Zanotti S, Hollenberg SM; Microcirculatory Alterations in Resuscitation and Shock Investigators. Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med. 2007 Jan;49(1):88-98, 98.e1-2. Epub 2006 Nov 7.</citation>
    <PMID>17095120</PMID>
  </reference>
  <reference>
    <citation>Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004 Sep;32(9):1825-31.</citation>
    <PMID>15343008</PMID>
  </reference>
  <reference>
    <citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77.</citation>
    <PMID>11794169</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>April 16, 2013</results_first_submitted>
  <results_first_submitted_qc>June 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2013</results_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cooper Health System</investigator_affiliation>
    <investigator_full_name>Dr. Trzeciak</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Severe sepsis</keyword>
  <keyword>Septic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We enrolled septic patients in the Emergency Department and Intensive Care Unit</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Nitric Oxide</title>
          <description>Subjects receive inhaled nitric oxide (40 parts per million) for six hours.</description>
        </group>
        <group group_id="P2">
          <title>Sham (Comparator)</title>
          <description>Subjects receive sham inhaled nitric oxide for six hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Nitric Oxide</title>
          <description>Subjects receive inhaled nitric oxide (40 parts per million) for six hours.</description>
        </group>
        <group group_id="B2">
          <title>Sham (Comparator)</title>
          <description>Subjects receive sham inhaled nitric oxide for six hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="15"/>
                    <measurement group_id="B2" value="58" spread="20"/>
                    <measurement group_id="B3" value="58" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Sequential Organ Failure Assessment (SOFA) Score</title>
        <time_frame>0-24 hours from protocol initiation</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Sublingual Microcirculatory Flow Index (MFI)</title>
        <description>The MFI is a continuous scale from 0-3, with 3.0 being better outcome and 0.0 being worse outcome.</description>
        <time_frame>0-2 hours of study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Subjects receive inhaled nitric oxide (40 parts per million) for six hours.</description>
          </group>
          <group group_id="O2">
            <title>Sham (Comparator)</title>
            <description>Subjects receive sham inhaled nitric oxide for six hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sublingual Microcirculatory Flow Index (MFI)</title>
          <description>The MFI is a continuous scale from 0-3, with 3.0 being better outcome and 0.0 being worse outcome.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.19" upper_limit="0.04"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.13" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lactate Clearance (Blood)</title>
        <time_frame>0-2 hours of study drug administration</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for the duration of hospital stay, an average of 5 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Nitric Oxide</title>
          <description>Subjects receive inhaled nitric oxide (40 parts per million) for six hours.</description>
        </group>
        <group group_id="E2">
          <title>Sham (Comparator)</title>
          <description>Subjects receive sham inhaled nitric oxide for six hours.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen Trzeciak, MD, MPH</name_or_title>
      <organization>Cooper University Hospital</organization>
      <phone>856-342-3342</phone>
      <email>trzeciak-stephen@cooperhealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

